<DOC>
	<DOCNO>NCT00595907</DOCNO>
	<brief_summary>New blood test become available detect either latent active tuberculosis . These test - accord CDC replace tuberculin skin test - measure production gamma-interferon ( cytokine ) peripheral lymphocyte ( white cell ) expose antigen highly specific mycobacterium tuberculosis ( bacteria responsible tuberculosis ) . Our hypothesis production gamma-interferon would much high begin treatment end , decline gamma-interferon secretion could indicator clinical response treatment .</brief_summary>
	<brief_title>Results Interferon-Gamma Release Assay After Treatment Tuberculosis</brief_title>
	<detailed_description>Patients either treat active culture prove tuberculosis ( TB ) complete treatment precede 6 month recruit . Exclusion criterion : HIV infection previous TB . Interferon gamma release assay ( T-SPOT.TB , Oxford Immunotec ) sample 2 first week treatment , end treatment 6 month later . T-SPOT.TB analyse qualitatively ( pos/neg ) quantitatively ( Spot form unit : SFU ) determine high rate negative test end treatment 6 month treatment initially . Paired sample analyse compare SFU count begin treatment end treatment , SFU count end treatment 6 month later . Clinical response treatment record , well treatment failure relapse .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>culture prove tuberculosis age &lt; 18 prior tuberculosis HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>interferon gamma release assay</keyword>
	<keyword>treatment</keyword>
</DOC>